223 related articles for article (PubMed ID: 23687292)
1. Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
Tang MW; Rhee SY; Bertagnolio S; Ford N; Holmes S; Sigaloff KC; Hamers RL; de Wit TF; Fleury HJ; Kanki PJ; Ruxrungtham K; Hawkins CA; Wallis CL; Stevens W; van Zyl GU; Manosuthi W; Hosseinipour MC; Ngo-Giang-Huong N; Belec L; Peeters M; Aghokeng A; Bunupuradah T; Burda S; Cane P; Cappelli G; Charpentier C; Dagnra AY; Deshpande AK; El-Katib Z; Eshleman SH; Fokam J; Gody JC; Katzenstein D; Koyalta DD; Kumwenda JJ; Lallemant M; Lynen L; Marconi VC; Margot NA; Moussa S; Ndung'u T; Nyambi PN; Orrell C; Schapiro JM; Schuurman R; Sirivichayakul S; Smith D; Zolfo M; Jordan MR; Shafer RW
J Infect Dis; 2013 Jun; 207 Suppl 2(Suppl 2):S70-7. PubMed ID: 23687292
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
[TBL] [Abstract][Full Text] [Related]
3. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
[TBL] [Abstract][Full Text] [Related]
4. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy.
Etiebet MA; Shepherd J; Nowak RG; Charurat M; Chang H; Ajayi S; Elegba O; Ndembi N; Abimiku A; Carr JK; Eyzaguirre LM; Blattner WA
AIDS; 2013 Feb; 27(4):553-61. PubMed ID: 23079810
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
Skhosana L; Steegen K; Bronze M; Lukhwareni A; Letsoalo E; Papathanasopoulos MA; Carmona SC; Stevens WS
PLoS One; 2015; 10(2):e0118145. PubMed ID: 25659108
[TBL] [Abstract][Full Text] [Related]
7. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
Parikh UM; Bacheler L; Koontz D; Mellors JW
J Virol; 2006 May; 80(10):4971-7. PubMed ID: 16641288
[TBL] [Abstract][Full Text] [Related]
8. K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data.
Recordon-Pinson P; Papuchon J; Reigadas S; Deshpande A; Fleury H
PLoS One; 2012; 7(5):e36549. PubMed ID: 22615779
[TBL] [Abstract][Full Text] [Related]
9. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.
Hosseinipour MC; van Oosterhout JJ; Weigel R; Phiri S; Kamwendo D; Parkin N; Fiscus SA; Nelson JA; Eron JJ; Kumwenda J
AIDS; 2009 Jun; 23(9):1127-34. PubMed ID: 19417582
[TBL] [Abstract][Full Text] [Related]
10. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
[TBL] [Abstract][Full Text] [Related]
11. First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Clumeck N; Mwamba C; Kabeya K; Matanda S; Vaira D; Necsoi C; Kadiebwe D; Delforge M; Kasamba E; Milolo C; Ilunga J; Kapend L
AIDS; 2014 May; 28(8):1143-53. PubMed ID: 25028911
[TBL] [Abstract][Full Text] [Related]
12. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
[TBL] [Abstract][Full Text] [Related]
13. The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.
Li S; Ouyang J; Zhao B; An M; Wang L; Ding H; Zhang M; Han X
BMC Infect Dis; 2020 Feb; 20(1):123. PubMed ID: 32046664
[TBL] [Abstract][Full Text] [Related]
14. Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
Gregson J; Kaleebu P; Marconi VC; van Vuuren C; Ndembi N; Hamers RL; Kanki P; Hoffmann CJ; Lockman S; Pillay D; de Oliveira T; Clumeck N; Hunt G; Kerschberger B; Shafer RW; Yang C; Raizes E; Kantor R; Gupta RK
Lancet Infect Dis; 2017 Mar; 17(3):296-304. PubMed ID: 27914856
[TBL] [Abstract][Full Text] [Related]
15. International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.
Grant PM; Taylor J; Nevins AB; Calvez V; Marcelin AG; Wirden M; Zolopa AR
Antimicrob Agents Chemother; 2010 Apr; 54(4):1520-5. PubMed ID: 20124005
[TBL] [Abstract][Full Text] [Related]
16. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.
Margot NA; Isaacson E; McGowan I; Cheng AK; Schooley RT; Miller MD
AIDS; 2002 Jun; 16(9):1227-35. PubMed ID: 12045487
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in Cambodia.
Nouhin J; Madec Y; Ngo-Giang-Huong N; Ferradini L; Nerrienet E
PLoS One; 2013; 8(8):e73744. PubMed ID: 24015311
[TBL] [Abstract][Full Text] [Related]
18. K65R, TAMs and tenofovir.
Miller MD
AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
[TBL] [Abstract][Full Text] [Related]
19. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
Hoffmann CJ; Ledwaba J; Li JF; Johnston V; Hunt G; Fielding KL; Chaisson RE; Churchyard GJ; Grant AD; Johnson JA; Charalambous S; Morris L
Antivir Ther; 2013; 18(7):915-20. PubMed ID: 23751421
[TBL] [Abstract][Full Text] [Related]
20. Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
Ross LL; Rouse E; Gerondelis P; DeJesus E; Cohen C; Horton J; Ha B; Lanier ER; Elion R;
J Antimicrob Chemother; 2010 Feb; 65(2):307-15. PubMed ID: 20008905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
